Evaluating Investigational Drug PLN-74809 in Participants with Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)
Not Recruiting
18 years - 75 years
All
Phase
2
5 participants needed
1 Location
Brief description of study
The purpose of this study is to determine the safety and tolerability of an experimental medication PLN-74809 to treat primary Sclerosing Cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts (small tubes) inside and outside the liver.
Participants will visit the study center 8 times within 22 weeks.
Compensation maximum amount you will be paid is $700.
Detailed description of study
The purpose of this study is to determine the safety and tolerability of an experimental medication PLN-74809 to treat primary Sclerosing Cholangitis (PSC), a rare, long-term liver disease affecting the bile ducts (small tubes) inside and outside the liver.
Participants will visit the study center 8 times within 22 weeks.
Compensation maximum amount you will be paid is $700.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Sclerosing Cholangitis, PSC, liver
-
Age: 18 years - 75 years
-
Gender: All
Updated on
11 Sep 2024.
Study ID: 843393
